English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

over 14 million cancer cases were diagnosed worldwide in 2012, and cancer incidence is expected to increase in the coming years (3, 9). The rising numbers of cancer survivors in many countries makes the identification of new therapeutic options an increasingly pressing issue (5). Tumor recurrence and metastasis is the most frequent cause of morbidity and mortality in cancer survivors and thus need to be a focus for new therapeutic developments. A central issue in the treatment of metastatic cancers is that these tumors gain resistance to chemotherapeutic and targeted biological agents (2, 4, 7). Despite the healthcare and economic burdens associated with cancer recurrence, many aspects of the basic biology and physiology of tumor metastasis remain poorly understood. Many open questions remain about the triggers or predispositions that lead to early invasion of cancer cells away from the primary tumor, or that then favor intravasation or long-term survival of tumor cells in secondary organs.

Cell and Molecular Processes in Cancer Metastasis: an AJP-Cell Physiology set of Themed Reviews